Navigation Links
Vion Pharmaceuticals Submits New Drug Application for Onrigin(TM)
Date:2/17/2009

s. Onrigin's ability to generate meaningful complete responses after a single sixty-minute infusion makes its utility in this patient population particularly attractive."

About Onrigin

Onrigin (laromustine) Injection, formerly known as Cloretazine(R) (VNP40101M), is a novel alkylating agent. Onrigin has been evaluated in over 800 patients in 16 clinical trials to date, including a pivotal Phase II trial in patients sixty years of age or older with de novo poor-risk AML. There are four clinical trials of Onrigin underway: (i) the continuation of the pivotal Phase II trial; (ii) a Phase III trial with standard remission-induction therapy in patients with AML and myelodysplastic syndromes (MDS); (iii) a Phase I/II trial in combination with cytarabine in elderly patients with AML; and (iv) a Phase I/II trial in combination with temozolomide in patients with brain tumors.

About Acute Myeloid Leukemia (AML)

The American Cancer Society estimates that 13,290 new cases of AML were diagnosed in the U.S. in 2008. AML is primarily a disease of the elderly, with a median age at onset of 67 years. Compared to younger patients, older AML patients have a lower rate of response to currently available induction chemotherapy and shorter overall survival due, in part, to unfavorable prognostic factors such as a higher incidence of adverse cytogenetics and frequent co-morbidities. In addition, patients with risk factors such as advanced age and poor performance status tolerate current induction treatments poorly. A 2005 study by Lang et al, based on data from the National Cancer Institute's Survey of Epidemiological and End Results (SEER) database, indicated that palliative care is given to the majority of elderly patients with AML in the U.S., providing additional evidence that new treatment options are needed for this population.

About Vion

Vion Pharmaceu
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
2. XTL Biopharmaceuticals Announces Appointment of David Grossman and Boaz Shweiger to Board of Directors
3. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
5. Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
6. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
7. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
8. Tigris Pharmaceuticals Files IND Application for GGTI-2418
9. Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
10. XTL Biopharmaceuticals to Convene Extraordinary Shareholders Meetings after Receipt of Shareholder Letter
11. Transcept Pharmaceuticals to Present at 11th Annual BIO CEO & Investor Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--DowAgroSciencesCana...s,adivisionofThompsonsLimitedofBlenheim,Ontario.Th...nces,currentseedsbusinessasthecompanyanticipatesth...SciencesHerbicideTolerantTraitTechnologyincornin20... ,, "Thisacquisitionbringstogethertwostrongprog...
(Date:11/24/2009)...-Asia/--NODPharmaceuticalsInc.announced,theUSPaten...cationfor,itsnano-particleoraldeliveryorNODtechnol...htoincorporatepeptidesor,proteinsintobio-adhesiven...administeredasinjections.NODtechnologyisaplatformt...ssuchasinsulin,interferon,growthhormone,exenatide...
(Date:11/24/2009)...beenmetforpatientswithadvanced-stage,orrecurrenten...re-FirstCall/-AEternaZentarisInc.(NASDAQ: AEZS ;TS...nyfocusedonendocrinetherapyandoncology,todayannoun...etedcytotoxicpeptideconjugate,AEZS-108(formerlyAN-...ancer.Inapersonalizedhealthcareapproach,thestudyse...
(Date:11/24/2009)...ewswire/--HealthRoboticstodayannounced,thatithasfo...nvestors.ThisrecentlyformedToronto-basedcompanywil...illmarket,install,andsupport,HealthRobotics,i.v.Ro...yproductofferingsi.v.STATION(TM),i.v.SOFT(TM),andO...istanceonan"asneeded,basis"toitsstrategicpartnersh...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2
...h Park MADISON OpGen, Inc. has added two new me...omas Pyle. The company is looking to bring in seas...he next level, according to Dan Broderick, managin... , ,They bring lots of experience with company ope...hey have long, successful careers in business and ...
...y figures show no reported venture investment acti...ear. Both total venture capital and initial ventur...as released by PricewaterhouseCoopers, Thomson Ven...sociation. Ten other states also showed $0 activit...money, according to the survey, with California re...
...ializing in patient-specific molecular data and pe...ts president and chief executive officer, it annou...esident and CEO of Pel-Freez Clinical Systems , l...ar biology and serologic products for solid organ ...icant growth and eventual acquisition under Langel...
Other Biology Technology:OpGen adds Thomas Pyle and James Ogle to board of directors 2MoneyTree Survey reports no venture investment activity in Wisconin in Q2 2MoneyTree Survey reports no venture investment activity in Wisconin in Q2 3MoneyTree Survey reports no venture investment activity in Wisconin in Q2 4MoneyTree Survey reports no venture investment activity in Wisconin in Q2 5MoneyTree Survey reports no venture investment activity in Wisconin in Q2 6
(Date:11/24/2009)... atomic-level action of a remarkable class of ring...rchers with the Lawrence Berkeley National Laborat...n crystallography beamline at the Advanced Light S...es in gene expression and replication, and are vit...l as infectious agents, such as the human papillom...
(Date:11/24/2009)...at constitutes fish food is a matter of debate. A ...fish get almost 50 percent of their carbon from tr...ween the terrestrial and aquatic ecosystems. , B...shows this is not likely to be true. Algae provide...e, according to research published this week in th...
(Date:11/23/2009)...hington, D.C. The community-associated strain of ...ria resistant to most common antibioticsposes a fa...is making its way into hospitals, according to a s... Diseases . , The new threat is easily picked u...aces and has increased the overall burden of MRSA ...
Breaking Biology News(10 mins):Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4Fish food fight: Fish don't eat trees after all, says new study 2Fish food fight: Fish don't eat trees after all, says new study 3New study finds MRSA on the rise in hospital outpatients 2IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 1IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 2IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 3IBM Analytics Expands To Help Governments Around World Build Smarter Systems 54203 4Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement 54200 1Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement 54200 2Plasma Protein Therapeutics Association Urges CMS For Appropriate Hospital Outpatient Drug Reimbursement 54200 3BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 1BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 2BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 3BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels 13502 4
...T LAFAYETTE, Ind. - Chemical engineers have develo...an inexpensive way of making diamondlike crystals ...logies. , The method, developed at Purdue Univers...licon template containing precisely spaced holes t...air. The template is immersed in water on top of w...
...orld was in shock when in 2001 the Talibans destro...han region of Bamiyan. Behind those statues, there...5th to 9th century A.D. The caves also suffered fr...atural environment, but today they have become the...ed, thanks to experiments performed at the Europea...
...er twenty-five years of investigating, analyzing, ...ers, neighbors, and even surviving victims, crimin...of the worlds most respected experts on the motiva...n SERIAL KILLERS AND SADISTIC MURDERERS: UP CLOSE ...is wealth of experience with the criminal mind to ...
Other Biology News:Findings a step toward making new optical materials 2Findings a step toward making new optical materials 3Findings a step toward making new optical materials 4Findings a step toward making new optical materials 5Synchrotron light unveils oil in ancient Buddhist paintings from Bamiyan 2A chilling glimpse inside the minds of dangerous criminals 2
Alkaline Phosphatase (E. coli C75) from GE Healthcare, formerly Amersham Biosciences
...and cDNA Labeling Kit with CyScribe GFX Purificati...ication of Cy3- and Cy5-labeled cDNA.Optimized rea...ling and purification.Flexible and optimized proto... with either Cy3- or Cy5-labeled nucleotides.Relia...
...ling Kit with CyScribe GFX Purification Kit, 24 re...3- and Cy5-labeled cDNA.Optimized reagents are pac...fication.Flexible and optimized protocols can be u...Cy3- or Cy5-labeled nucleotides.Reliable purificat...
Canine serum from Equitech-Bio
Biology Products: